Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $917,950.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $16.69, for a total transaction of $917,950.00. Following the transaction, the chief executive officer now owns 276,017 shares of the company’s stock, valued at $4,606,723.73. This represents a 16.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Saurabh Saha also recently made the following trade(s):

• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.93, for a total transaction of $876,150.00.
• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00.

Centessa Pharmaceuticals Stock Performance

CNTA opened at $15.75 on Monday. The firm has a market capitalization of $2.08 billion, a PE ratio of -10.29 and a beta of 1.54. Centessa Pharmaceuticals plc has a twelve month low of $7.75 and a twelve month high of $19.09. The firm’s 50-day moving average price is $16.47 and its 200 day moving average price is $16.41. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Analysts Set New Price Targets

A number of research firms have weighed in on CNTA. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday, February 10th. Morgan Stanley reaffirmed an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Finally, TD Cowen began coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $26.00.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of CNTA. GF Fund Management CO. LTD. acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth about $31,000. GAMMA Investing LLC boosted its position in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after acquiring an additional 865 shares during the last quarter. Barclays PLC boosted its position in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company’s stock worth $89,000 after acquiring an additional 4,952 shares during the last quarter. BNP Paribas Financial Markets acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth about $162,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at about $171,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.